Director Michelle Doig resigns; shareholders elect two Class I directors at annual meeting

On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).

Proposal 1 - Election of Directors. The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Peter Lebowitz, M.D., Ph.D. 31,822,504 3,372 Frank P. McCormick, Ph.D., F.R.S., D. Sc. 25,654,119 6,171,757 There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.

Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 34,535,875 3,440 0 There were zero broker non-votes and 13,805,126 no votes regarding this proposal.